Skip to main content

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model





) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 0.2%. By the end of trading, Vivus rose 13 cents (1.2%) to $10.94 on light volume. Throughout the day, 1.3 million shares of Vivus exchanged hands as compared to its average daily volume of 3.7 million shares. The stock ranged in a price between $10.71-$11 after having opened the day at $10.71 as compared to the previous trading day's close of $10.81. Other companies within the Drugs industry that increased today were:

Anacor Pharmaceuticals



), up 26%,

ACADIA Pharmaceuticals



), up 23.9%,




), up 17.5%, and

Cleveland BioLabs



), up 8.9%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. Vivus has a market cap of $1.09 billion and is part of the health care sector. Shares are down 20.1% year to date as of the close of trading on Wednesday. Currently there are seven analysts that rate Vivus a buy, two analysts rate it a sell, and three rate it a hold.

TheStreet Ratings rates Vivus as a


. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

On the negative front,

Idera Pharmaceuticals



), down 10.2%,

Pharmacyclics Incorporated



), down 8.4%,

ARCA biopharma



), down 7.8%, and

ADVENTRX Pharmaceuticals



), down 7.8%, were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE